Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Cash & Current Investments (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Cash & Current Investments for 16 consecutive years, with $81.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Current Investments rose 2.46% to $81.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $81.2 million, a 2.46% increase, with the full-year FY2025 number at $81.2 million, up 2.46% from a year prior.
  • Cash & Current Investments was $81.2 million for Q4 2025 at Anika Therapeutics, up from $80.2 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $124.2 million in Q4 2021 to a low of $75.4 million in Q1 2025.
  • A 5-year average of $99.3 million and a median of $96.9 million in 2021 define the central range for Cash & Current Investments.
  • Peak YoY movement for Cash & Current Investments: tumbled 32.69% in 2021, then surged 34.04% in 2022.
  • Anika Therapeutics' Cash & Current Investments stood at $124.2 million in 2021, then decreased by 2.64% to $121.0 million in 2022, then decreased by 21.38% to $95.1 million in 2023, then decreased by 16.7% to $79.2 million in 2024, then increased by 2.46% to $81.2 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Cash & Current Investments are $81.2 million (Q4 2025), $80.2 million (Q3 2025), and $77.1 million (Q2 2025).